Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 20/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804153 | 0.89 | SLC16A1 (0.56) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL4803574 | 0.88 | SLC16A1 (0.54) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL4923253 | 0.87 | SLC16A1 (0.52) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3827309 | 0.87 | SLC16A1 (0.52) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3829938 | 0.86 | SLC16A1 (0.73) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL4803012 | 0.86 | SLC16A1 (0.67) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3831634 | 0.85 | SLC16A1 (0.63) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3833844 | 0.84 | SLC16A1 (0.62) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3834003 | 0.84 | SLC16A1 (0.62) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL4799270 | 0.84 | SLC16A1 (0.58) | SLC16A1CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361660-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-04-22 | — | — | US | disclosed |
| EP-1412362-B1 | THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | SLC16A1 1397/4885CYP2C9 63/4885CYP3A4 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.